Company Abnova (Taiwan) Corporation

Equities

4133

TW0004133004

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Sector Bio Therapeutic Drugs

End-of-day quote Taiwan S.E. Other stock markets 06:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
31.4 ^TWD	-0.63%		+0.80%	-10.54%

Feb. 29	Abnova Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Abnova Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

ABNOVA (TAIWAN) CORPORATION is a Taiwan-based company principally engaged in the manufacturing and sales of antibodies and proteins. The Company's products mainly include monoclonal antibodies, polyclonal antibodies, protein fragments, full-length proteins, active proteins, antibody pairs, fluorescence in situ hybridization probe and others. The Company's monoclonal and polyclonal antibodies are primarily applied in medical testing reagents, agricultural testing, industrial purification, medical treatment and other fields. Its proteins are mainly applied in medical testing reagents, agricultural testing, medical treatment, protein engineering and other fields. Its products are mainly traded in Taiwan, Americas and Europe.

TWD in Million	2022	Weight	2023	Weight	Delta
Monoclonal Antibody 31.7 %	133	32.2 %	121	31.7 %	-8.85%
Others 23.4 %	90	21.9 %	89	23.4 %	-0.89%
Paired Antibody 20.0 %	93	22.6 %	77	20.0 %	-17.84%
Protein 16.6 %	67	16.2 %	63	16.6 %	-5.35%
Multiple Antibodies 6.4 %	31	7.5 %	25	6.4 %	-20.19%
Testing Equipment 1.9 %	-2	-0.5 %	7	1.9 %	-484.85%

TWD in Million	2022	Weight	2023	Weight	Delta
America 50.4 %	-	-	193	50.4 %	-
Europe 24.8 %	-	-	95	24.8 %	-
Other Countries 21.5 %	53	12.9 %	82	21.5 %	+54.94%
Taiwan 3.2 %	29	7.1 %	12	3.2 %	-57.76%

Managers	Title	Age	Since
Pei Ju Jih CEO	Chief Executive Officer	-	18-06-30
Wilber Huang CHM	Chairman	58	-
I Ling Tung IRC	Investor Relations Contact	-	-
Ya Ping Chang AUD	Comptroller/Controller/Auditor	-	-
Shukuan Chen PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Yueh Hung Chen BRD	Director/Board Member	60	20-06-18
Wilber Huang CHM	Chairman	58	-
Jia Hsie Lin BRD	Director/Board Member	73	17-06-22
Chi Ching Chiu BRD	Director/Board Member	53	21-12-13
Fang Wen Chen BRD	Director/Board Member	39	20-06-16
Shao De Ye BRD	Director/Board Member	57	17-06-22
Jin Jun Su BRD	Director/Board Member	55	17-06-22

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	60,554,000	44,635,594 ( 73.71 %)	0	73.71 %

Name	Equities	%	Valuation
DFA Australia Ltd. 0.001805 %	1,093	0.001805 %	1 091 NT$

Abnova Taiwan Corp.

108 Jhouzih Street 9th floor

114, Taipei

http://www.abnova.com.tw

address Abnova (Taiwan) Corporation(4133)

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ABNOVA (TAIWAN) CORPORATION	-10.54%	58.89M
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B
ARGENX SE	+4.40%	22.94B
BIONTECH SE	-12.15%	22.34B
GENMAB A/S	-4.36%	19.25B
WUXI APPTEC CO., LTD.	-39.98%	17.08B
BEIGENE, LTD.	-10.04%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.16B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B

Bio Therapeutic Drugs